Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive dose-finding study of BAY 1747846 (gadoquatrane) vs gadobutrol for CNS MRI
jRCT2080225116Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of gadoquatrane in acute neurological injury (2 arms), sponsored by Bayer. Primary endpoint: Primary diagnostic efficacy endpoint. Started Mar 2020; status: completed.
02
Drugs
gadoquatrane
03
Conditions
acute neurological injury
Beyond the preview
Go deeper on jRCT2080225116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225116.